0000899243-19-017421.txt : 20190619 0000899243-19-017421.hdr.sgml : 20190619 20190619161659 ACCESSION NUMBER: 0000899243-19-017421 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190617 FILED AS OF DATE: 20190619 DATE AS OF CHANGE: 20190619 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mostafa Adam S. CENTRAL INDEX KEY: 0001738081 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 19906225 MAIL ADDRESS: STREET 1: C/O ABPRO CORPORATION STREET 2: 65 CUMMINGS PARK DRIVE CITY: WOBURN STATE: MA ZIP: 01801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 955 MASSACHUSETTS AVENUE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 955 MASSACHUSETTS AVENUE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-17 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001738081 Mostafa Adam S. C/O X4 PHARMACEUTICALS, INC. 955 MASSACHUSETTS AVENUE, 4TH FLOOR CAMBRIDGE MA 02139 0 1 0 0 CFO and Treasurer Common Stock 2019-06-17 4 A 0 10564 0.00 A 10564 D Stock Option (right to buy) 14.75 2019-06-17 4 A 0 15847 0.00 A 2029-06-17 Common Stock 15847 15847 D Grant of restricted stock units to the Reporting Person under the Issuer's 2017 Equity Incentive Plan, with each restricted stock unit representing the contingent right to receive one share of common stock on the applicable vesting date. No amount was paid upon grant of the units. The restricted stock units vest in four equal annual installments on June 30, 2020, June 30, 2021, June 30, 2022 and June 30, 2023, subject to the Reporting Person continuing to provide services through each such date. Represents unvested restricted stock units. 25% of the shares subject to the option shall vest on June 17, 2020, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option on the last day of each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date. /s/ Adam S. Mostafa 2019-06-19